Sarcode Bioscience Inc.
Brisbane, CA, US· latest recorded location
SARCODE BIOSCIENCE INC. is named on 25 US grants and 57 published applications in this corpus. Its most frequent classification is C07D (Heterocyclic compounds).
- Granted patents
- 25
- Published applications
- 57
- Inventors
- 27
- Granted in 2026 so far
- 0
- Most recent grant
- 30 Apr 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 3 | 0 |
| 2012 | 1 | 3 |
| 2013 | 3 | 2 |
| 2014 | 3 | 11 |
| 2015 | 6 | 21 |
| 2016 | 3 | 4 |
| 2017 | 1 | 5 |
| 2018 | 2 | 3 |
| 2019 | 3 | 3 |
| 2020 | 0 | 2 |
By publication year.
Technology areas
Share of 82 documents
- C07DHeterocyclic compounds79
- A61PTherapeutic uses of medicines69
- A61KMedicines and medical preparations62
- C07CAcyclic or carbocyclic compounds48
- G01NInvestigating or analysing materials by determining their chemical or physical properties40
- A61BMedical diagnosis and surgery39
- C04BLime, magnesia9
- C07BGeneral methods of organic chemistry7
- B01JChemical or physical processes4
- A61FFilters implantable into blood vessels1
Recent patents
- Continuous flow carboxylation reaction30 Apr 2019US 10,273,212 B2
- LFA-1 inhibitor and methods of preparation and polymorph thereof26 Feb 2019US 10,214,517 B2
- Compositions and methods for treatment29 Jan 2019US 10,188,641 B2
- Modulators of cellular adhesion13 Nov 2018US 10,124,000 B2
- Crystalline pharmaceutical and methods of preparation and use thereof13 Feb 2018US 9,890,141 B2
- Crystalline pharmaceutical and methods of preparation and use thereof19 Mar 2020US 2020/0087287 A1
- Ocular distribution and pharmacokinetics of lifitegrast formulations9 Jan 2020US 2020/0009130 A1
- Lfa-1 inhibitor and methods of preparation and polymorph thereof19 Dec 2019US 2019/0382389 A1
- Continuous flow carboxylation reaction3 Oct 2019US 2019/0300485 A1
- Modulators of cellular adhesion9 May 2019US 2019/0134022 A1
Most cited
By later US patents
- Compositions and methods for treatment of eye disorders84US 8,168,655 B22012
- Crystalline pharmaceutical and methods of preparation and use thereof35US 8,367,701 B22013
- Crystalline pharmaceutical and methods of preparation and use thereof33US 8,080,562 B22011
- Compositions and methods for treatment of eye disorders29US 8,084,047 B22011
- LFA-1 inhibitor and methods of preparation and polymorph thereof29US 9,085,553 B22015